Osmina
Composition
Osmina Tablet: Each film coated tablet contains Ospemifene INN 60 mg.
Indication
Osmina is an estrogen agonist/antagonist indicated for the treatment of
moderate to severe dyspareunia & vaginal dryness, a symptom of vulvar
and vaginal atrophy, due to menopause.
Dosage & Administration
Osmina is an estrogen agonist/antagonist which has agonistic effects on
the endometrium. Use of Osmina should be for the shortest duration
consistent with treatment goals and risks for the individual women.
One tablet should be taken orally once daily with food or as directed by
the physician.
Olmepin
Composition
Olmepin™ 20/5 Tablet: Each film coated tablet contains Olmesartan Medoxomil USP 20 mg & Amlodipine Besilate BP equivalent to Amlodipine 5 mg.
Olmepin™ 40/5 Tablet: Each film coated tablet contains Olmesartan Medoxomil USP 40 mg & Amlodipine Besilate BP equivalent to Amlodipine 5 mg.
Indication
Olmepin™ is indicated for the treatment of hypertension, alone or with other antihypertensive agents.
Olmepin™ may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals.
Dose & Administration:
Initial Therapy: The usual starting dose of Olmesartan Medoxomil/Amlodipine Besilate is 20/5 mg
one tablet once daily. The dosage can be increased after 1 to 2 weeks of therapy to a maximum dose of 40/10 mg once daily as needed to control blood pressure. This combination may be taken with or without food. This combination may be administered with other antihypertensive agents.
Initial therapy with this combination products is not recommended in patients >75 years old or with hepatic impairment.
Replacement therapy: Olmesartan Medoxomil/Amlodipine Besilate may be substituted for its individually titrated components. When substituting for individual components, the dose of one or both of the components can be increased if blood pressure control has not been satisfactory.
Add-on Therapy: Olmesartan Medoxomil/Amlodipine Besilate may be used to provide additional blood pressure lowering for patients not adequately controlled with Amlodipine (or another dihydropyridine Calcium Channel Blocker) alone or with Olmesartan Medoxomil (or another angiotensin II receptor blocker) alone or as directed by the physician.
Orc
Composition:
OrcTM Tablet: Each film coated tablet contains Ketorolac Tromethamine USP 10 mg.
OrcTM 30 IV/IM injection: Each 1 ml ampoule contains Ketorolac Tromethamine USP 30 mg.
OrcTM 60 IV/IM injection: Each 2 ml ampoule contains Ketorolac Tromethamine USP 60 mg.
Indication:
OrcTM tablets are indicated for short term management of moderate postoperative pain and acute & chronic musculoskeletal pain as a continuation of treatment.
OrcTM injections are indicated for short term management of moderate to serve acute post-operative pain.
Dose & Administration:
OrcTM tablets: Ketorolac Tromethamine 10 mg tablet 4-6 hourly; Elderly 6-8 hourly. Maximum dose is 40 mg daily.
OrcTM Injection: Adult patient (<65 years): Ketorolac Tromethamine is for administration by intramuscular or intravenous injection. Initial dose is 60 mg IM or 30 mg IV. Maintenance dose is 30 mg IM/IV 6 hourly.
Odafen
Composition:
Odafen™ 120: Each film coated tablet contains Fexofenadine
Hydrochloride USP 120 mg.
Odafen™ 180: Each film coated tablet contains Fexofenadine
Hydrochloride USP 180 mg.
Odafen™ Suspension: Each 5 ml suspension contains Fexofenadine Hydrochloride USP 30 mg.
Indication:
Seasonal Allergic Rhinitis:
Odafen™ tablet are indicated for the relief of symptoms
associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Odafen™ oral suspension is indicated for the relief of symptoms associated with seasonal allergic rhinitis in children 2 to 11 years of age. Symptoms to treat
effectively:
sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes.
Chronic Idiopathic Urticaria:
Odafen™ of Chronic Idiopathic Urticaria in adults and children 6 years of age and
older.
Odafen™ manifestations of Chronic Idiopathic Urticaria in children 6 months to 11 years
of age. Fexofenadine Hydrochloride significantly reduces pruritus and the number
of wheals.
Olmeben Plus
Composition:
Olmeben™ Plus 20/12.5 Tablet: Each film coated tablet contains Olmesartan Medoxomil USP 20 mg & Hydrochlorothiazide BP 12.5 mg
Indication:
It is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy.
Dose & Administration:
Hypertension
The usual starting dose of Olmeben™ Plus 20/12.5 is one tablet once daily. Dosing should be
individualized. Depending on the blood pressure response, the dose may be titrated at intervals of
2-4 weeks.
Patients with Renal Impairment:
The usual regimens of therapy with Olmeben™ Plus 20/12.5 may be followed provided the patient's creatinine clearance is >30 mL/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides. So, Olmeben™ Plus 20/12.5 is not recommended. Patients with Hepatic Impairment: No dosage adjustment is necessary with hepatic impairment.
Or as directed by the physician.
Olmeben
Composition:
Olmeben™ 20 Tablet: Each film coated tablet contains Olmesartan Medoxomil USP 20 mg.
Olmeben™ 40 Tablet: Each film coated tablet contains Olmesartan Medoxomil USP 40 mg.
Indication:
It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Dose & Administration:
The usual starting dose of Olmesartan is 20 mg once daily. Dosing should be individualized. Depending on the blood pressure response, the dose may be increased after 2 weeks to 40 mg. Olmesartan may be administered with or without food. No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance < 40 ml/min) or with moderate to marked hepatic dysfunction. If blood pressure is not controlled by Olmesartan alone, a diuretic may be added. Olmsartan may be administerd with other antihypertensive agents. Or as directed by the physician.
